UT Southwestern Medical Center
NAA logo
Adult Treatment Panel III Guidelines by National Cholesterol Education Program & National Heart, Lung, and Blood Institute

Abstract | Faculty | Curriculum | Research | Student Resources | Clinical Resources | Nutrition Links | WAVE | National NAA | Home

Step 7: Drug Tx

The table below lists drug classes along with the recommended daily doses, effects
on lipid levels, side effects, and contraindications for use in cholesterol treatment.

Statins are the most widely recommended class of drugs used for treatment of elevated
cholesterol. These have been shown to decrease the risk of heart disease and stroke in addition to lowering cholesterol levels. They work by inhibiting the natural production of cholesterol in the body. Some individuals may require a combination therapy approach
of other drug classes listed in the chart below.

Refer to the table in Step 5 to determine the necessity of drug therapy based
on the patients current LDL measurement and goal with any existing risk factors.

  • Drug therapy may be considered in conjunction with TLC for CHD
    and CHD risk equivalents.
  • Drug therapy may also be considered if after 3 months TLC has been
    unsuccessful and risk factors are present.

Drug Class Agents and Daily Doses Lipid/Lipoprotein Effects Side Effects Contraindications
HMG CoA
reductase
inhibitors (statins)
Lovastatin (20-80 mg),
Pravastatin (20-40 mg),
Simvastatin (20-80 mg),
Fluvastatin (20-80 mg),
Atorvastatin (10-80 mg),
Cerivastatin (0.4-0.8 mg)
LDL-C 18-55%
HDL-C 5-15%
TG 7-30%
Myopathy
Increased liver
enzymes
Absolute:
Active or chronic liver
disease
Relative:
Concomitant use of certain
drugs*
Bile acid
Sequestrants
Cholestyramine (4-16 g)
Colestipol (5-20 g)
Colesevelam (2.6-3.8 g)
LDL-C 15-30%
HDL-C
3-5%
TG No change or
increase
Gastrointestinal
distress
Constipation
Decreased
absorption of other
drugs
Absolute:
dysbeta-lipoproteinemia
TG >400 mg/dL
Relative:
TG >200 mg/dL
Nicotinic acid Immediate release (crystalline)
nicotinic acid (1.5-3 gm),
extended release nicotinic acid
(Niaspan ®) (1-2 g), sustained
release nicotinic acid (1-2 g)
LDL-C 5-25%
HDL-C
15-35%
TG
20-50%
Flushing
Hyperglycemia
Hyperuricemia (or
gout)
Upper GI distress
Hepatotoxicity
Absolute:
Chronic liver disease
Severe gout
Relative:
Diabetes
Hyperuricemia
Peptic ulcer disease
Fibric acids Gemfibrozil (600 mg BID)
Fenofibrate (200 mg)
Clofibrate (1000 mg BID)
LDL-C 5-20% (may
be increased in patients
with high TG)
HDL-C
10-20%
TG
20-50%
Dyspepsia
Gallstones
Myopathy
Absolute:
Severe renal disease
Severe hepatic disease

*Cyclosporine, macrolide antibiotics, various anti-fungal agents, and cytochrome P-450 inhibitors (fibrates and niacin
should be used with appropriate caution).

 
Web Tools
ATP III Guidelines
Step 1: Lipid Profile
Step 2: Presence of CHD
Step 3: Risk Factors
Step 4: 10-year Risk
Step 5: Risk Category
Step 6: TLC
Step 7: Drug Tx
Step 8: Metabolic Syndrome
Step 9: Triglycerides

Abstract | Faculty | Curriculum | Research | Student Resources | Clinical Resources | Nutrition Links | WAVE | National NAA | Home

UT Southwestern Medical Center
5323 Harry Hines, Dallas, TX 75390
214-648-2890
Page created and maintained by: Lona Sandon, MEd, RD, LD
Email: NAA@UTSouthwestern.edu


Last updated: 10/3/03

   Search this site or the web        powered by FreeFind
 
  Site search Web search